tilsotolimod
mAbexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2019 (NCT03865082)
Timeline
Indications
Studied for
Mechanism of action
- Toll-like receptor 9AGONIST
Toll-like receptor 9 agonist
- Toll-like receptor 9INHIBITOR
TLR9 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297838 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04270864 | Phase 1 | Feb 29, 2020 | Institut Gustave Roussy |
| NCT04196283 | Phase 1 | Dec 14, 2019 | AbbVie, Aceragen, Inc/ |
| NCT04126876 | Phase 2 | Nov 1, 2019 | Aceragen, Inc/, Free University of Amsterdam |
| NCT03865082 | Phase 2 | Jun 30, 2019 | Aceragen, Inc/, Bristol-Myers Squibb |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aceragen, Inc/ | For profit | 3 | 1 | 2 | 2019 |
| AbbVie | For profit | 1 | 1 | 1 | 2019 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2019 |
| Free University of Amsterdam | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1